ArticleOphthalmology and therapy2026
Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the PLANET Study.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pachychoroid diseases of the macula: an update.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
25 authors.
Funding
Abstract
introductionThe PLANET study demonstrated that intravitreal aflibercept 2 mg injection (IAI) monotherapy was non-inferior to IAI with rescue photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) at 2 years. This follow-up study assessed the long-term outcomes 6 years after initiation of IAI therapy in the PLANET cohort.
methodsThis was a non-interventional cohort study of 72 patients with PCV from six international sites who originally completed the PLANET study. Outcomes were assessed during a recall visit at ~6 years from PLANET enrollment. Data collected included best-corrected visual acuity (BCVA), optical coherence tomography, treatment exposure, and adverse events. Patients were treated according to standard of care after exiting from the PLANET study.
resultsOf 72 participants, 32 were randomized to IAI monotherapy and 40 to IAI with rescue PDT. Of those randomized to IAI with rescue PDT, 11 (15.2%) received rescue PDT during the entire study period over 6 years. Mean ± standard deviation (SD) BCVA improved by 14.6 ± 10.3 letters at 2 years but declined to baseline by 6 years (-0.3 ± 21.8 letters). At year 6, 45.8% of eyes had BCVA ≥ 69 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, while 23.6% had < 36 ETDRS letters. Polypoidal lesions were present in 69.4% at year 2 versus 29.2% at year 6. Patients received a mean ± SD of 10.2 ± 2.9 anti-vascular endothelial growth factor (anti-VEGF) injections between years 2-6. Outcomes were better in reimbursed versus non-reimbursed regions. Multivariable analysis showed that younger age and better mean BCVA at year 2 predicted more favorable long-term vision. PDT received at any time was not associated with overall mean BCVA at year 6, although it was associated with a lower risk of ≥ 15-letter loss.
conclusionAt 6 years, initial visual gains from aflibercept therapy were not maintained; however, nearly half of the eyes had BCVA ≥ 69 letters, and a large proportion achieved polypoidal lesion regression.
trial registrationClinicalTrials.gov identifier, NCT002120950.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.